Skip to content

Effect of hydrolyzed whey protein supplementation on clinical outcomes in patients with esophageal cancer under ERAS concept

Effect of hydrolyzed whey protein supplementation on clinical outcomes in patients with esophageal cancer under ERAS concept

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092184
Enrollment
Unknown
Registered
2024-11-12
Start date
2024-11-15
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal carcinoma

Interventions

intervention group:Patients without nutritional risk: Hydrolyzed whey protein 10g orally orally. Patients at nutritional risk (NRS= 3 points): Hydrolyzed whey protein 10 g orally twice a day + generic
control group:For patients without nutritional risk: Maltodextrin 10g orally twice daily
regularly assess nutritional risk.For patients with nutritional risk (NRS = 3): Maltodextrin 10g orally twice daily + general nutritional supplement 50g orally once daily.Postoperative enteral nutriti

Sponsors

Huadong Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Older than 18 years old. 2. The patient is aware of the study protocol and agrees to participate in the study. 3. Cytologically or histologically confirmed esophageal malignancy. 4. Surgery is planned for the near future (2 weeks). 5. Preoperative nutritional risk (NRS-2002=3 points).

Exclusion criteria

Exclusion criteria: 1. Patients with other tumors. 2. Previous gastric surgery or esophageal surgery. 3. Serious life-threatening complications (such as massive bleeding, serious infection). 4. Infusion of albumin or drugs that affect protein metabolism in the past month.

Design outcomes

Primary

MeasureTime frame
Postoperative clinical outcomes;

Secondary

MeasureTime frame
nutritional status;Muscle mass and function;Markers of inflammation;Intestinal permeability;

Countries

China

Contacts

Public ContactJiang Wu

Huadong Hospital Affiliated to Fudan University

Jennifer.wz@hotmail.com+86 137 7424 5811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026